Coronary thrombolysis with clot-selective plasminogen activators

Area of Science:

• Cardiology
• Biochemistry
• Pharmacology

Background:

• Acute myocardial infarction treatment is actively researched, with thrombolysis being a key area.
• Current research focuses on developing fibrin-specific thrombolytic agents for improved clot selectivity.
• Fibrin-specific agents minimize systemic plasmin generation, reducing bleeding complications compared to older agents.

Purpose of the Study:

• To investigate the efficacy and safety of fibrin-specific thrombolytic agents for acute myocardial infarction.
• To compare intravenous administration of fibrin-specific agents with intracoronary administration.
• To evaluate recombinant tissue-type plasminogen activator (rt-PA) in clinical trials.

Main Methods:

• Review of current research on coronary thrombolysis agents.
• Analysis of clinical trial data for acylated streptokinase-plasminogen complex, pro-urokinase, and tissue-type plasminogen activator (t-PA).
• Focus on intravenous administration of rt-PA in patients with acute myocardial infarction.

Main Results:

• Acylated streptokinase-plasminogen complex showed high reopening rates but significant bleeding complications.
• Pro-urokinase demonstrated fibrin-specific activity in preclinical studies, but human trials are pending.
• Intravenous rt-PA achieved approximately 75% recanalization in acute myocardial infarction patients with minimal systemic fibrinolytic activation.

Conclusions:

• Fibrin-specific thrombolytic agents, particularly rt-PA, represent a promising advancement in acute myocardial infarction treatment.
• Intravenous administration of rt-PA offers advantages in applicability and speed of initiation.
• rt-PA demonstrates effective coronary recanalization with an improved safety profile regarding bleeding risk.